The polycomb group protein EZH2 is involved in progression of prostate cancer

By S. Varambally, S. Dhanasekaran, Ming Zhou, T. Barrette, Chandan Kumar-Sinha, M. Sanda, Debashis Ghosh, K. Pienta, R. Sewalt, A. Otte and 2 more. Nature, 2002

2,749 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/759057d2ef5cb21b2ac85f9ba934f75eb6de6ce7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Peter A. Jones
2. Ryuji Hamamoto
3. Yi Zhang
4. Yusuke Nakamura
5. S. Baylin
6. J. Simon
7. K. Helin
8. D. Reinberg

In Pulmonary and Respiratory Medicine

1. Arul M. Chinnaiyan
2. J. Massagué
3. Mark A. Rubin
4. D. Nguyen
5. E. Hay

Citations in the corpus

• Transcriptome Sequencing Identifies PCAT-1, a Novel lincRNA Implicated in Prostate Cancer Progression (2011, background): “Because of this notable profile, we hypothesized that PCAT-1 may have coordinated expression with the oncoprotein EZH2 , a core PRC2 protein that is upregulated in solid tumors and contributes to a metastatic phenotyp”
• Cancer metastasis: building a framework. (2006, background): “As a recent example, ectopic overexpression of the polycomb group protein EZH2, which results in alterations in chromatin remodeling, correlates with metastasis and poor overall survival in prostate cancer patients (Varambally et al., 2002).”
• Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells (2008, background): “Recent molecular studies have disclosed that alterations of global histone modification play a role in human tumorigenesis (Varambally et al., 2002).”
• Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity (2004, background): “Moreover, we and others have shown that both EZH2 and EED are essential for proliferation of primary and tumor cells (Varambally et al, 2002; Bracken et al, 2003).”
• Genetic determinants of cancer metastasis (2007, background): “: EZH2 overexpression is predictive of invasive growth in metastatic prostate and breast cancer”
• SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells (2004, background): “One of the polycomb group genes EZH2 , is up-regulated in hormone-refractory, metastatic prostate cancer”
• Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. (2006, background): “The increased expression of several other genes in Table 3, including MMP9, WNT5A, EZH2 , and E2F3 , has also been associated previously with higher grade local prostate cancer, disease recurrence, or metastatic prostate cancer (20, 23, 40, 41).”
• Molecular genetics of prostate cancer: new prospects for old challenges. (2010, background): “One key modification associated with prostate carcinogenesis is trimethylation of lysine residue 27 of histone H3 (H3K27-me3), which is mediated by the histone methyltransferase enzyme Ezh2, a key oncogenic driver of advanced disease and metastasis (Varambally et al. 2002).”